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Human α2-macroglobulin (A2M) is an abundant 
protease inhibitor in plasma which regulates many 
proteolytic processes and is involved in innate 
immunity. A2M’s unique protease-trapping 
mechanism of inhibition is initiated when a 
protease cleaves within the exposed and highly 
susceptible “bait region”. As the wildtype bait 
region is permissive to cleavage by most human 
proteases, A2M is accordingly a broad-spectrum 
protease inhibitor. In this study, we extensively 
modified the bait region in order to identify any 
potential functionally important elements in the 
bait region sequence and to engineer A2M 
proteins with restrictive bait regions which more 
selectively inhibit a target protease. A2M in which 
the bait region was entirely replaced by glycine-
serine repeats remained fully functional and was 
not cleaved by any tested protease. Therefore, this 
bait region was designated as the “tabula rasa” 
bait region and used as the starting point for 
further bait region engineering. Cleavage of the 
tabula rasa bait region by specific proteases was 
conveyed by the insertion of appropriate substrate 
sequences, e.g. basic residues for trypsin. 
Screening and optimization of tabula rasa bait 
regions incorporating matrix metalloprotease 2 
(MMP2) substrate sequences produced an A2M 
that was specifically cleaved by MMPs and 
inhibited MMP2 cleavage activity as efficiently as 
wildtype A2M. We propose that this approach can 
be used to develop A2M-based protease inhibitors 
which selectively inhibit target proteases, which 
might be applied towards the clinical inhibition of 
dysregulated proteolysis as occurs in arthritis and 
many types of cancer. 
Introduction 
Proteases constitute the largest enzyme 
family in humans with 641 currently identified 
members (1). In addition, they are common 
virulence factors produced by viruses, bacteria, 
and parasites. As they are involved in virtually 
every type of biological event and pathogenic in 
many diseases, they represent potential drug 
targets (1). However, the therapeutic targeting of 
proteases, such as MMPs in cancer, has proven 
difficult because of broad protease inhibition by 
small molecule therapeutics (2-4). The 
development of new therapeutics with restricted 
inhibitory activities that selectively target 
individual proteases has the potential to both 
improve the efficacy and alleviate toxicities in 
protease-targeting treatment strategies.  
Human A2M is a 720 kDa homo-
tetrameric protein that is abundant in plasma and 
is archetypical for the alpha-macroglobulin (αM) 
protease inhibitor family, whose human members 
also include A2M-like protein 1 (A2ML1) and 
pregnancy zone protein (PZP). A2M has a unique 
mechanism of inhibition where it collapses around 
proteases and irreversibly sequesters them from 
protein substrates (5). This conformational 
collapse is triggered by peptide bond hydrolysis 
within the bait region, a 39-residue sequence that 
is unstructured and poorly evolutionarily 
conserved, but is rapidly and preferentially 
cleaved by most proteases regardless of their 









associated with covalent conjugation of the 
protease by a thiol ester bond that is initially 
buried within A2M and exposed upon its 
proteolysis-induced conformational change; 
although covalent conjugation is required for 
protease trapping by the monomeric αMs, 
tetramers like A2M can trap proteases non-
covalently (8-11). As a consequence of its 
conformational change, A2M reveals a binding 
site that interacts with a scavenger receptor, low-
density lipoprotein receptor-related protein 1 
(LRP1), and this interaction quickly removes 
A2M-protease complexes from circulation 
through internalization and endosomal 
degradation, primarily in the liver (12,13). 
In order for a protease to be inhibited by 
an αM protease inhibitor, the protease must be 
able to cleave within the αM’s bait region. The 
bait region of A2M contains 15 of the 20 
canonical amino acids, permitting cleavage by 
most proteases with simple substrate recognition 
(e.g. only involving the P1 or P1’ residue), and 
also has an MMP cleavage site (14,15) (sequence: 
PEGL) (Fig. 1A). In vitro, A2M has been shown 
to inhibit proteases involved in coagulation and 
fibrinolysis, e.g. plasma kallikrein, thrombin, FXa, 
and plasmin (7,16-18), inflammatory proteases, 
e.g. cathepsin G, human neutrophil elastase, and 
mast cell chymase (19,20), and proteases that 
remodel the extracellular matrix, e.g. MMPs and 
ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs) proteases (14,15,21). 
A2M can also inhibit pathogen-expressed 
proteases, including P. gingivalis gingipain R, S. 
aureus GluC (a.k.a. V8), and HIV protease 1, and 
delivers these potential antigens to LRP1-
expressing antigen-presenting cells such as 
macrophages and dendritic cells (22-25). The 
addition of protease substrate sequences for 
proteases that are not inhibited by wildtype A2M 
into the bait region is sufficient to allow their 
inhibition, as has been demonstrated for furin, 
tobacco etch virus protease, and LysC (26-28). 
The αM protein superfamily includes the 
complement factors C3, C4, and C5, which are 
homologous to A2M and also undergo 
proteolysis-induced conformational changes (29). 
αM complement factors and the four subunits of 
the A2M homotetramer have a conserved 
structure which includes eight macroglobulin 
(MG) domains, a CUB domain, and the thiol ester 
(TE) domain (Fig. 1B-C) (30). Crystal structures 
of each complement factor in its native and 
protease-cleaved conformation have been 
determined (31-37), but not for A2M. A2M can be 
made to collapse into a conformation that is 
highly similar to its protease-cleaved 
conformation by aminolysis of its thiol ester (e.g. 
using methylamine (MA)) (5,38,39), and the 
crystal structure of A2M-MA has been determined 
as a surrogate for its protease-cleaved 
conformation (40). We have recently developed a 
low-resolution model of native A2M using 
negative stain electron microscopy, small-angle 
X-ray scattering, and cross-linking-mass 
spectrometry (41). This model indicates that 
proteases must enter the interior of native A2M to 
access and cleave the bait regions, at which point 
A2M collapses and closes off its entrances, 









The bait regions occupy the interior space of 
native A2M and may interact with each other, as 
suggested by the formation of inter-subunit 
disulfides upon the introduction of cysteine 
residues into the bait region (42). 
The precise molecular mechanism by 
which bait region cleavage triggers A2M’s 
conformational collapse is not known. In the αM 
complement factors, the anaphylactic domain 
corresponds to the bait region of αM protease 
inhibitors, and its removal by proteolysis is 
thought to perturb the adjacent MG3 and MG8 
domains, thereby initiating a conformational 
change (36). However, while the anaphylactic 
domain has a rigid α-helix structure (32) and is 
evolutionarily conserved across species, the bait 
region is unstructured and poorly conserved (Sup. 
Fig. S1), and it is unclear how it could participate 
in an equivalent triggering mechanism. While the 
reaction of A2M’s thiol ester with nucleophiles 
(e.g. lysine side chain ε-amino groups on the 
surface of proteases) takes place during or after its 
conformational change (43), its amino- or 
hydrolysis is not required for the conformational 
change to take place, as A2M lacking a thiol ester 
is still induced to change its conformation by 
proteolysis (44), as are the thiol ester-lacking αM 
proteins C5 and chicken ovostatin (10,37). 
In this study, we have produced and 
characterized recombinant A2M proteins with 
modified bait regions which investigate the bait 
region’s functional role and demonstrate the 
design of new protease inhibitors. We found that 
A2M’s bait region can be replaced in its entirety 
with 13 Gly-Gly-Ser triplets without preventing 
A2M from assembling into its usual homo-
tetrameric structure or assuming its native 
conformation. This tabula rasa bait region was 
not initially cleaved by any of 12 tested proteases, 
but could be cleaved by trypsin, LysC, or MMP2 
upon introducing an appropriate cleavage site into 
its sequence. Bait region cleavage of tabula rasa 
A2Ms resulted in protease conjugation through 
A2M’s thiol ester, the induction of A2M’s 
conformational collapse, and protease inhibition, 
as demonstrated for trypsin and MMP2. An 
MMP2 substrate bait region that was selectively 
cleaved by MMPs was identified by screening 
using 10 human proteases. Further optimization of 
the bait region yielded a tabula rasa A2M which 
inhibited MMP2 as efficiently as wildtype A2M. 
Altogether, these results demonstrate an approach 
to developing more specific A2M-based protease 
inhibitors through bait region engineering, and 
have identified several factors that are important 
during bait region design, including the cleavage 
site position and bait region length. 
Results 
Bait region substitution with 13 Gly-Gly-Ser 
triplets produces A2M that is tetrameric, native, 
and inducible. 
The bait region is both ground zero for 
A2M’s proteolytically induced conformational 
change and the major determiner of which 
proteases are inhibited by A2M. However, the low 
conservation of the bait region sequence across 
species (Sup. Fig. S1) suggests that it has no 
essential structure or sequence motifs. In order to 









putative structural features from the bait region 
and determine the extent to which it tolerates 
modification, we entirely replaced the 39-residue 
bait region sequence with 13 Gly-Gly-Ser repeats, 
chosen for their solubility and low susceptibility 
to proteolysis (Fig. 2A).  
The resulting tabula rasa bait region 
could be incorporated into recombinant A2M, 
resulting in a tabula rasa A2M protein that was 
predominantly tetrameric and in its native 
conformation, with an intact thiol ester apparent 
from the formation of characteristic heat-induced 
autolysis products in SDS-PAGE (Fig. 2B-C). 
Upon aminolysis of its thiol ester with 
methylamine, tabula rasa A2M underwent a 
conformational collapse indistinguishable from 
that of wildtype A2M, as determined by pore-
limited native PAGE; however, tabula rasa A2M 
was not cleaved in its bait region by either trypsin 
or LysC, and remained in its native conformation 
despite proteolysis by these proteases outside of 
its bait region (Fig. 2B-C). While the majority of 
tabula rasa A2M assembled into the normal 
homotetramer, dimeric tabula rasa A2M that had 
failed to tetramerize was slightly more abundant 
than for wildtype A2M; dimers were removed 
during purification prior to all characterization 
(Sup. Fig. S2). Similarly, while the majority of 
tabula rasa A2M was in a native conformation, 
both fully collapsed A2M and conformations with 
an intermediate electrophoretic mobility were 
apparent in pore-limited native PAGE and more 
abundant than in wildtype A2M (Fig. 2B). Before 
using these proteins in quantitative protease 
inhibition assays, non-native A2M was depleted 
using LRP1-conjugated resin (Sup. Fig. S3). 
The TR K704 bait region added a lysine 
residue at position 704 and was cleaved by trypsin 
and LysC, which caused A2M to undergo a 
conformational collapse (Fig. 2A-C); as the 
wildtype bait region and the initial tabula rasa 
bait region contain no lysine residues, LysC 
cleaved these A2Ms in locations other than the 
bait region without inducing a conformational 
change, as has been previously reported (45). The 
protease-induced conformational change of A2M 
TR K704 activated its thiol ester and resulted in 
the formation of covalent conjugation products 
that were apparent as high-MW bands in reducing 
SDS-PAGE (Fig. 2C). Altogether, these results 
showed that while the wildtype bait region may 
make minor contributions towards A2M’s 
tetrameric assembly and the assumption of its 
native conformation, no part of its sequence is 
structurally or functionally essential. The majority 
of tabula rasa A2M is tetrameric and in a native 
conformation, and can undergo both a 
methylamine- or proteolysis-induced 
conformational change (if protease substrate sites 
are incorporated into the bait region). 
Bait region lysine residues can be conjugated by 
the thiol ester upon its proteolytic activation. 
Bait region cleavage of A2M TR K704 by 
both trypsin and LysC produced an intense band 
migrating as ~250 kDa in reducing SDS-PAGE 
that was not produced by trypsin-cleaved wildtype 
A2M (Fig. 2C). The bait region is spatially close 









activated (Fig. 1B-D), and we hypothesized that 
the nucleophilic ε-amine group of Lys704’s side 
chain might attack the thiol ester following 
proteolysis, conjugating the N- and C-terminal 
bait region cleavage fragments together into an 
aberrantly migrating ~180 kDa product. This 
proposed product of Lys704 auto-conjugation 
disappeared when 3-aminopropanenitrile (BAPN), 
a small nucleophile that reacts with the thiol ester 
after it is proteolytically exposed and out-
competes conjugation to other nucleophiles (9), 
was included alongside trypsin, demonstrating 
that it is formed through thiol ester-mediated 
conjugation (Fig. 3A). After cleavage of A2M TR 
K704 with Cy5-labeled trypsin, this band was not 
fluorescent and therefore does not contain trypsin 
(Fig. 3A). In fact, the product band became more 
intense upon cleaving A2M TR K704 with 
acetylated trypsin, which is not efficiently 
conjugated as it lacks primary amine groups (Fig. 
3A). LC-MS/MS analysis of the pepsin-digested 
product band identified a cross-linked peptide 
containing an isopeptide cross-link between the 
thiol ester Gln975 and the bait region Lys704 (Fig. 
3B). Furthermore, the band was not produced 
upon tryptic cleavage of tabula rasa A2M with a 
bait region arginine residue instead of a lysine 
residue (Sup. S4A-B). These results conclusively 
show that this band represents an auto-conjugation 
product of the thiol ester and a bait region lysine 
residue. 
Tabula rasa A2M proteins inhibit trypsin in a 
manner that is dependent on covalent conjugation.  
We proceeded to investigate the trypsin-
inhibiting ability of tabula rasa-based A2Ms 
using a fluorescently labeled gelatin substrate. In 
addition to A2M TR K704, bait regions 
incorporating an Arg704, Lys710, or Arg710 
residue were produced (Fig. 4A). These A2M 
proteins appeared similar to A2M TR K704 
during their initial characterization by 
electrophoresis (Sup. Fig. S4A-B). In order to 
quantitatively determine the inhibitory capacity of 
the native tabula rasa A2Ms, non-native A2M 
was depleted from these proteins using LRP1-
conjugated resin before all inhibitory assays (Sup. 
Fig. S3). A2M with the tabula rasa bait region 
was completely unable to inhibit trypsin, but 
incorporation of either lysine or arginine into the 
bait region conveyed inhibition of trypsin (Fig. 
4B). However, all four tabula rasa A2M with 
basic residues incorporated into their bait regions 
showed a decreased inhibitory capacity relative to 
recombinant wildtype A2M or plasma-purified 
A2M. Tabula rasa A2M with an arginine residue 
at position 704 or 710 possessed approximately 80% 
and 60% of the wildtype inhibitory capacity, 
respectively, while a lysine residue at these 
positions conveyed approximately 30% and 50% 
inhibition (Fig. 4B). 
To investigate the mechanistic 
explanation for these decreased inhibitory 
capacities, trypsin inhibition assays were repeated 
for plasma-purified A2M, A2M TR K710, and 
A2M TR R704 with and without BAPN, which 
out-competes covalent conjugation of other 
nucleophiles by A2M’s proteolytically activated 
thiol ester (9). The inhibition of trypsin by 
plasma-purified A2M was not affected by BAPN, 









covalent conjugation as has been previously 
reported (9), whereas both A2M TR K710 and 
A2M TR R704 demonstrated much lower 
inhibitory capacities in the presence of BAPN 
(Fig. 4C). These results show that trypsin 
inhibition by tabula rasa A2Ms is dependent on 
covalent protease conjugation, in contrast to 
wildtype A2M. 
Identification of an MMP2-cleavable bait region 
sequence with improved selectivity.  
After verifying that tabula rasa A2Ms 
retained the ability to inhibit proteases using the 
model protease trypsin, we designed four bait 
regions incorporating substrate sequences for 
human MMP2 (Fig. 5A), a potential therapeutic 
target in several types of cancer including ovarian 
cancer and pancreatic adenocarcinoma (46). Three 
of these substrate sequences (A21A, B74, and C9) 
were previously identified as MMP2 substrates 
using phage display (47), while the fourth (S1) is 
a generic MMP substrate. All four tabula rasa-
based MMP2 substrate bait regions and the 
wildtype bait region were cleaved by MMP2, but 
not the initial A2M tabula rasa (Fig. 5B-D). 
Despite the rapid formation of A2M-MMP2 
complexes (Sup. Fig. S5A), A2M was never fully 
bait region-cleaved even by a large excess of 
MMP2 (Sup. Fig. S5B), and A2M:MMP2 
complexes migrated with an intermediate 
electrophoretic mobility (Sup. Fig. S5C). These 
results resemble A2M’s reaction with plasmin 
(48-50) and may be a common feature of 
A2M:protease complex formation with larger 
proteases (>60 kDa). The incomplete bait region 
cleavage and intermediate electrophoretic 
mobility of A2M:MMP2 complexes was the same 
for wildtype A2M and the four tabula rasa A2Ms 
with MMP2 substrate sequences. 
We then tested whether the four MMP2 
substrate bait regions were cleaved by nine 
additional human proteases (plasmin, cathepsin G, 
MMP1, MMP3, MMP8, MMP13, ADAMTS4, 
ADAMTS5, and ADAMTS13) using reducing 
SDS-PAGE to assess bait region cleavage and the 
formation of high-MW conjugation products (Sup. 
Fig. S6). All assessed proteases except 
ADAMTS13 (which is highly specific towards 
von Willebrand factor (51,52)) were able to cleave 
wildtype A2M, while none were able to cleave 
A2M tabula rasa (Fig. 5B). The incorporation of 
any of the four MMP2 substrate sequences into 
the tabula rasa bait region conveyed cleavage by 
all tested MMPs, but they were differently cleaved 
by non-MMP proteases; for example, the C9 
substrate was the only one containing an arginine 
residue and was the only A2M to be cleaved by 
plasmin (Fig. 5A-B). Notably, the S1 substrate 
was only cleaved by MMPs (Fig. 5A-B), and the 
A2M TR S1 protein was therefore selected for 
further optimization as an MMP inhibitor with 
improved specificity relative to wildtype A2M. 
The native content of tabula rasa-based A2Ms is 
improved by shortening the bait region by seven 
residues or restoring the 10 C-terminal wildtype 
residues. 
The initial tabula rasa A2M proteins were 
expressed with an increased amount of non-native 
A2M compared to wildtype A2M. While this was 








this study, as native A2M could be purified using 
LRP1-based depletion prior to inhibitory assays, 
such non-native A2M constitutes a decrease in 
yield and its depletion would be difficult to scale 
up. In order to resolve this issue, we tested two 
altered tabula rasa bait regions (Fig. 6A). The first, 
TR∆7, was shortened by 7 residues to a total 
length of 32 residues, to compensate for the 
tabula rasa bait region possibly being effectively 
longer than the wildtype bait region due to altered 
dynamics, interactions, or secondary structure. 
The second, TR QRT4, re-introduced the C-
terminal quarter of the wildtype bait region; while 
the bait region sequence in generally is not 
conserved, there is a tendency towards acidic and 
hydrophobic residues in its C-terminal quarter 
preceding the α’NT region (Sup. Fig. S1) and 
analogous residues in C3 are positioned alongside 
the MG3 domain(32), suggesting that this 
sequence may coordinate the position of the bait 
region. In fact, both TR∆7 and TR QRT4 
improved the native content to that of wildtype 
A2M (Fig. 6B). TR∆7 is the preferable sequence 
for bait region design as it does not re-introduce 
any protease cleavage sites, in contrast to TR 
QRT4 (7). 
The position of the S1 substrate sequence within 
the TR∆7 bait region affects the efficiency of 
MMP2 inhibition. 
MMP2 inhibition by A2M was assessed 
using the same fluorescent gelatin substrate used 
in the trypsin inhibition assays. While all tabula 
rasa A2Ms incorporating the S1 substrate site 
were capable of inhibiting MMP2, the bait region 
length and cleavage site position were found to 
affect the inhibitory efficiency (Fig. 6C). While 
the TRΔ7 S1 I703 bait region conveyed inhibition 
that was equivalent to that of plasma-purified or 
wildtype recombinant A2M, the TRΔ7 S1 I710 
bait region, which was identical apart from the 
cleavage site position, inhibited with 
approximately 40% efficiency (Fig. 6C). The two 
39-residue long tabula rasa bait regions TR S1 
and TR S1 QRT4, which both incorporate the S1 
cleavage site at position 710, had approximately 
70% of the wildtype inhibitory capacity (Fig. 6C). 
These results demonstrate that tabula rasa A2Ms 
are capable of inhibiting MMP2 with the same 
efficiency as wildtype A2M, but that the bait 
region length and cleavage site position can affect 
the efficiency of protease inhibition and requires 
optimization. 
Discussion 
In this study, we have produced and 
characterized 12 variant A2Ms in order to 
elucidate the effects of the tabula rasa bait region 
substitution and demonstrate an approach to 
developing new protease inhibitors which 
selectively inhibit a target protease. Wildtype 
A2M is an efficient protease inhibitor with an 
extensive inhibitory repertoire, and it is well-
established that A2M can inhibit new proteases 
when an appropriate substrate sequence is added 
into the bait region (26-28). Furthermore, A2M is 
highly stable and has desirable pharmacokinetics, 
including a long circulatory half-life in its native 
conformation (12). Therefore, the main design 
challenge in developingA2M-based protease 
inhibitors is selectivity towards the target 









bait region provides one solution to this issue and 
can advantageously be used as the starting point 
for bait region design, as it removes all known 
cleavage sites of human proteases from the A2M 
bait region while preserving A2M’s structure and 
protease-inhibiting functionality. 
However, our investigation of tabula rasa 
bait regions incorporating MMP2 substrate 
sequences emphasizes a second challenge, which 
is the difficulty of finding substrate sequences that 
are truly specific to the target protease and will 
produce a completely selective A2M. Despite our 
testing of three distinct MMP2 motifs identified 
for MMP2 by phage display (47) as well as a 
generic MMP motif (Pro-X-X-hydrophobic), the 
resulting A2Ms were cleaved by all tested MMPs . 
Nonetheless, an A2M incorporating the S1 
substrate was not cleaved by any of the tested 
non-MMP proteases, which is a significant 
improvement in specificity compared to wildtype 
A2M. A2M-based protease inhibition strategies 
may be aided in the future by the identification of 
more specific MMP substrate sequences, as our 
understanding of the relationship between MMP 
structure and substrate preference continues to 
improve (53). Of course, other promising 
approaches are under investigation that do not rely 
on distinct substrate preferences, such as the 
highly specific blocking of MMPs using 
monoclonal antibodies (54) or active site-directed 
nanobodies (55). 
We have additionally shown how bait 
region factors affecting yield and inhibitory 
efficiency can be optimized. For example, the 
length of the tabula rasa bait region affected the 
formation of native A2M, and a shortened 32-
residue tabula rasa bait region was preferable to 
the initial 39-residue tabula rasa bait region. The 
addition of a lysine residue into the tabula rasa 
bait region resulted in auto-conjugation of the 
lysine by the thiol ester upon bait region cleavage. 
Although this auto-conjugation event did not 
appear to compete with the conjugation of trypsin, 
as similar conjugation of fluorescent trypsin by 
wildtype A2M and A2M TR K704 was observed, 
it may be relevant in the inhibition of other 
proteases and should be considered. This becomes 
especially important considering that the 
inhibition of trypsin by tabula rasa A2Ms was 
dependent on covalent protease conjugation; this 
is in contrast to wildtype A2M, which has been 
shown to inhibit several proteases (including 
trypsin) independent of covalent conjugation 
(9,56). We speculate that altered bait region 
dynamics may affect the accessibility of the bait 
region and allow proteases to cleave the substrate 
site without fully entering A2M’s internal cavity, 
in which case they cannot be trapped non-
covalently. Alternatively, an increased distance 
between tabula rasa bait regions might lengthen 
the duration between successive bait region 
cleavage events and thereby slow the closing of 
the trap, permitting proteases to escape A2M after 
a single bait region cleavage event. The relevance 
of rapid successive bait region cleavage is 
supported by the difference in inhibitory 
capacities between A2Ms containing bait region 
arginines or lysines, considering that trypsin 








lysine substrates (57). This difference in inhibition 
between lysine- and arginine-containing A2Ms 
persisted even in the presence of BAPN, 
indicating that it is not a consequence of thiol 
ester auto-conjugation to the bait region lysine. 
Furthermore, the position of a cleavage 
site within the tabula rasa bait region was found 
to affect A2M’s inhibitory stoichiometry towards 
MMP2, as seen when comparing the TR∆7 S1 
I710 and TR∆7 S1 I703 bait regions. This 
suggests that the tabula rasa bait region can be 
accessed from outside the A2M tetramer where 
the protease is not trapped upon A2M’s collapse, 
depending on the position of the cleavage site. It 
is unclear whether this is unique to the tabula rasa 
bait region or whether cleavage site position 
affects inhibition by wildtype A2M. The bait 
regions of wildtype A2M are sufficiently close to 
each other to allow disulfide formation (42), and 
they may interact with each other in a manner that 
is conducive to efficient protease trapping. 
Nonetheless, it was possible to identify cleavage 
site positions which conveyed MMP2 inhibition 
by tabula rasa A2M that was equivalent to 
wildtype A2M, showing that this is a critical but 
solvable issue in bait region design.  
The complete replacement of all bait 
region residues with Gly-Gly-Ser triplets without 
disruption of A2M’s proteolytically induced 
conformational change has mechanistic 
implications for A2M and the broader αM protein 
superfamily. It is currently unknown how bait 
region cleavage is sensed by A2M and triggers its 
conformational change. It has previously been 
proposed that the proteolytic removal of the 
anaphylactic domain (which corresponds to the 
bait region) in αM complement factors disrupts 
interactions between the anaphylactic, MG3, and 
MG8 domains, thus triggering the overall 
conformational change (36). Our results with 
tabula rasa A2M show that putative side chain-
dependent interactions of the bait region are 
neither required for the formation of native A2M 
or for inducing the conformational change. These 
observations make it improbable that the bait 
region participates in essential MG3/MG8-
stabilizing interactions. This may reflect a 
difference between A2M and the αM complement 
factors, but we consider it more likely that the 
fundamental aspects of the proteolytically induced 
conformational change are conserved within the 
αM superfamily, as the ubiquity of this 
conformational change in the superfamily 
suggests that it arose early in an ancestral protein. 
If this assumption is correct, another less obvious 
proteolysis-sensing trigger mechanism remains to 
be found. 
Proteases are important therapeutic targets 
in many diseases. As A2M is an efficient, 
irreversible, and broad-spectrum protease 
inhibitor, it could plausibly be used for protease-
inhibiting interventions in many contexts. For 
example, both endogenous patient-enriched A2M 
and recombinant A2M are under investigation for 
clinical treatment of osteoarthritis (58,59), where 
rampant cartilage degradation by MMPs is 
pathogenic. However, it is desirable to restrict 
these interventions to the target protease as much 









detrimental and/or dose-limiting, and will 
obfuscate the on-target effects that are under 
clinical investigation. Here, we have shown that 
A2M tolerates complete replacement of its bait 
region and have demonstrated how this can be 
used in order to develop rationally designed 




A pcDNA3.1(+) plasmid with the gene 
for wildtype A2M under control of a CMV 
promoter (44) was used for recombinant 
expression of A2M. The bait region sequence was 
changed using either site-directed mutagenesis or 
synthesis of new bait region sequences followed 
by restriction site cloning, depending on the extent 
of the changes. All cloning work was performed 
by GenScript. All bait region sequences are shown 
in Supplementary Table S1, and all full protein 
sequences are included in the supplementary 
information.  
Another pcDNA3.1(+) plasmid encoding 
human proMMP2 with two StrepII tags at the N-
terminal end of its activation peptide was prepared 
by gene synthesis and cloning into pcDNA3.1(+), 
by Genscript. 
Expression and purification of A2M 
All recombinant A2Ms were expressed in 
HEK293 FreeStyle cells using a standard transient 
transfection protocol. Briefly, 25 kDa linear 
polyethyleneimine (Polysciences) and plasmid 
DNA were incubated for 10 min in antibiotic-free 
FreeStyle medium (Thermo Fisher Scientific) at a 
4:1 w/w PEI:DNA ratio, then slowly dripped into 
a culture of cells at a density of 1 million cells per 
mL, to a final DNA concentration of 1 µg per mL 
culture. After 4 days, the supernatant was 
harvested by spinning down the cells at 1500 x g 
and adding pH 7.4 HEPES to a final concentration 
of 50 mM.  
Purification of recombinant A2M was 
performed using an established protocol (16,60). 
Supernatants were first run through a Zn
2+
-loaded 
Chelating HiTrap column (GE Healthcare) and 
eluted with 50 mM EDTA, 150 mM NaCl, 100 
mM sodium acetate, pH 7.4. The EDTA eluate 
was dialyzed against 20 mM HEPES at pH 7.4, 
then loaded onto a HiTrap Q column (GE 
Healthcare) and eluted by a gradient of 0-400 mM 
NaCl (with a constant 20 mM HEPES at pH 7.4). 
Fractions containing A2M were pooled, 
concentrated by ultrafiltration, and purified by 
size exclusion chromatography on a Sephacryl S-
300 HR (GE Healthcare), using a 20 mM HEPES, 
150 mM NaCl, pH 7.4 running buffer (HEPES-
buffered saline, HBS). Endogenous human A2M 
was purified from plasma provided by a healthy 
volunteer using this same protocol; prior to the 
first chromatography step, 4% polyethylene glycol 
(PEG) was used to precipitate and remove 
contaminant plasma proteins, after which 16% 
PEG was used to precipitate and isolate A2M for 
further purification. 
Protease production 
N-terminally StrepII-tagged proMMP2 
was expressed using the same transient 









treated with streptavidin to remove free biotin. 
ProMMP2 was then purified by StrepTactin 
affinity chromatography (IBA Lifesciences), 
followed by size exclusion chromatography on a 
Superdex 200 Increase (GE Healthcare). 
ProMMP2 was activated using 1 mM APMA by 
incubating for 15 minutes at 37 °C, followed by 
desalting into HBS with 10 mM CaCl2 using a 
PD-10 column (GE Healthcare). 
Recombinant expression, purification, and 
activation of MMP-1, -3, -8, and -13, as well as 
ADAMTS-4 lacking the C-terminal spacer 
domain and ADAMTS-5 lacking the C-terminal 
thrombospondin domain, was performed as 
previously described (61-66). Plasminogen was 
purified from human plasma as previously 
described (67) and activated by adding urokinase 
to a 1:100 w/w ratio and incubating at 37 °C for 
two hours. Human neutrophil cathepsin G was 
purchased from Athens Research & Technology, 
bovine pancreatic trypsin from Sigma Aldrich, 
and lysyl endopeptidase (LysC) from FUJIFILM 
Wako Pure Chemical Corporation. 
Reaction of A2M with methylamine and proteases 
 To aminolyze A2M’s thiol ester, 
methylamine (pH 8) was added to 250 mM and 
incubated for at least 45 minutes at 37 °C. To 
assess the cleavage of A2M by trypsin and LysC, 
proteases were added to a 2.2:1 mol/mol ratio of 
protease:A2M and incubated for five minutes at 
37 °C. The digestion was then inhibited using the 
serine protease inhibitor PMSF (2 mM, 15 
minutes, room temperature). To assess the 
cleavage of A2M by MMP2, MMP2 was added to 
A2M in HBS with 10 mM CaCl2 to a 6:1 mol/mol 
ratio of MMP2:A2M, incubated for 15 minutes at 
37 °C, and then inhibited using 20 mM EDTA. 
When cleaving A2M using other human proteases, 
incubation lasted one hour at 37 °C in HBS with 
10 mM CaCl2, and PMSF or EDTA was used to 
inhibit serine proteases and metalloproteases, 
respectively. 
In-gel digest using pepsin and LC-MS/MS 
analysis 
The suspected auto-conjugation product 
observed upon proteolytic activation of A2M TR 
K704 mutant was investigated by digesting the 
auto-conjugation product separated by reducing 
SDS-PAGE with pepsin and subsequent LC-
MS/MS analysis. Gel bands were excised, shrunk 
with acetonitrile, and then swelled with 0.1 % v/v 
acetic acid, pH 3. Shrinking and swelling were 
repeated twice to wash the gel bands. The gel 
bands were shrunk a final time, dried, and then 
swelled in 0.1 % v/v acetic acid, pH 3 with pepsin 
added to a final 1:20 w/w ratio of pepsin:sample. 
Digestion with pepsin was carried out overnight at 
37 °C. Peptides from the digested samples were 
then purified using pipette tips packed with 
POROS 50 R2 C18 resin (PerSeptive Biosystems). 
Approximately 250 nanograms of peptide 
were analyzed by LC-MS/MS with an EASY-nLC 
1200 (Thermo Fisher Scientific) and an Orbitrap 
Eclipse Tribrid mass spectrometer (Thermo Fisher 
Scientific). A data-dependent acquisition method 
selected peptides for fragmentation by high-
energy collision dissociation (HCD) and MS2; 









from the thiol ester-covering LQMPYGCGEQN 
peptide, precursors were selected for a second 
MS2 scan using electron transfer dissociation 
(ETD), which resulted in the flagging of relevant 
precursor peptides with ETD scans. 
Cross-linked peptide identification was 
performed manually. The most abundant 
precursor whose HCD MS2 spectrum triggered 
ETD and therefore contained LQMPYGCGEQN’s 
b2 and b3 fragment ions had a mass 
corresponding to the LQMPYGCGEQN and 
FTNSKIRKPKMCGGSGGSGGSGGSGGK 
peptides cross-linked by an isopeptide bond. Both 
cysteines were propionamidylated as they had 
been reduced prior to SDS-PAGE; there were no 
other amino acid modifications. Fragment ions in 
this precursor’s HCD MS2 spectrum were 
manually annotated with a mass tolerance of 10 
ppm. Manual annotation identified ions resulting 
from fragmentation in both peptides, in addition to 
b- and y-type single-fragmented ions. The raw 
data file containing the annotated spectrum has 
been deposited to the ProteomeXchange 
Consortium via the PRIDE (68) partner repository 
with the dataset identifier PXD023651. 
Depletion of non-native A2M using LRP1-
conjugated resin 
The A2M-binding fragment of LRP1, 
cluster 1B (69), was expressed with two N-
terminal StrepII tags and a C-terminal Fc region 
from human IgG1, and purified as previously 
described
11
. 600 µg LRP1 were conjugated onto 
200 mg of NHS-activated agarose (Pierce) in 0.15 
M TEAB, 0.15 M HEPES, pH 8.3, for two hours 
at room temperature with mixing on a rotator. 
Conjugation was quenched with 50 mM Tris-HCl, 
pH 8. 
Non-native recombinant A2M was 
depleted by adding 10 mM CaCl2 to the A2M 
solution and incubating it for at least two hours 
with the LRP1 resin on a rotator at room 
temperature. The flowthrough from the resin was 
then saved as the depleted A2M sample, and the 
resin was regenerated first by eluting with three 
rounds of 50 mM EDTA in HBS, followed by 
three rounds of washing with 10 mM CaCl2 in 
HBS. The abundance of native A2M in the sample 
before and after depletion was then assessed by 
pore-limited native PAGE.  
Determining A2M’s inhibition of protein substrate 
cleavage by trypsin and MMP2 
The inhibition of trypsin by A2M was 
investigated using a fluorescently labelled gelatin 
substrate. 2.1 pmol (11.9 nM) of active trypsin 
was reacted with 0-8.6 pmol (0-47.7 nM) of A2M 
in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl2 
pH 8 for 15 min at 37 °C. DQ Gelatin From Pig 
Skin (Invitrogen) was added to a final 
concentration of 0.1 mg/ml. The fluorescence 
(excitation at 485 nm and emission at 520 nm) of 
the unquenched digestion products of DQ gelatin 
after 2 min at 37 °C were measured in a FLUOstar 
Omega plate reader (BMG LABTECH). Where 
noted, 50 mM BAPN was included in the initial 
reaction buffer with trypsin and A2M. All 
reactions were performed in triplicates.  
Similar reactions were carried out to 









wildtype A2M and the mutants TR+ S1, TRd7 S1, 
TR S1, and TR d7 I703. The only difference in the 
experimental set-up was that 1.4 pmol (7.5 nM) of 
MMP2 was reacted with 0-2.7 pmol (0-15 nM) of 
A2M and fluorescence was measured after 10 min 
of incubating the gelatin with the A2M/MMP2 
reactions. 
Data availability 
The raw data file containing the spectrum 
identifying A2M TR K704’s auto-conjugation 
product peptide has been deposited to the 
ProteomeXchange Consortium via the PRIDE (68) 
partner repository with the dataset identifier 
PXD023651. 
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Full protein sequences for all recombinant 
A2M proteins are included in the supplementary 
information. 
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A2M   α2-macroglobulin 
A2ML1  A2M-like protein 1 
ADAMTS  A disintegrin and metalloproteinase with thrombospondin motifs 
BAPN   3-aminopropanenitrile 
BR  Bait region 
CUB   C1r/C1s, urchin embryonic growth factor, and bone morphogenetic protein 1 
DQ   1,4-diethyl-decahydro-quinoxaline 
ETD   Electron transfer dissociation 
HBS  HEPES-buffered saline, here defined as 20 mm HEPES-NaOH, 150 mM NaCl, pH 7.4 
HCD   High-energy collision-induced dissociation 
LNK   Linker region 
LRP1   Low-density lipoprotein receptor-related protein 1 
MA   Methylamine 
MG   Macroglobulin domain 
MMP   Matrix metalloprotease 
PMSF  Phenylmethanesulfonyl fluoride 
PZP   Pregnancy zone protein 
TE   Thiol ester domain 
TR   The tabula rasa bait region 
αM  Alpha-macroglobulin protein superfamily 









FIGURE 1. A2M’s bait region sequence, domain organization, and mechanism of action. (A) The bait 
region sequence of A2M (residues 690-728), as well as the beginning and end of the adjacent MG6a and 
LNK domains. (B) A schematic representation of the domain configuration in a native A2M subunit. (C) The 
domains of an A2M subunit. (D) The inhibitory mechanism of A2M, shown using models derived from 
negative stain electron microscopy, small angle X-ray scattering, and cross-linking-mass spectrometry (41). 
A2M consists of four identical subunits (colored separately). Proteases must enter native A2M in order to 
cleave its bait region, which triggers a collapse of A2M that engulfs the protease. Up to two proteases can be 
trapped in close succession.  
 
FIGURE 2. The conformation and functionality of tabula rasa A2M. (A) Sequences of the wildtype, 
tabula rasa (TR) and TR K704 bait regions. Cleavage sites for trypsin (arginine and lysine residues) are 
indicated. (B) Pore-limited native PAGE of A2M incorporating the three given bait region sequences. As 
indicated, A2M samples were treated with methylamine, trypsin, or LysC. All constructs originally 
demonstrated the slow electrophoretic mobility that is characteristic of A2M’s native conformation; upon 
methylamine aminolysis or bait region cleavage, A2M collapses and demonstrates a faster electrophoretic 
mobility. Wildtype A2M and A2M TR K704 were both collapsed by trypsin, while only A2M TR K704 was 
collapsed by LysC; A2M TR was not collapsed by either protease. (C) Reducing SDS-PAGE of the same 
A2M samples as in panel B. The thiol ester-dependent heat-fragmentation bands (TE 120 and TE 60) 
disappeared upon methylamine treatment. Bait region cleavage of A2M gives its ~85 and ~95 N- and C-
terminal fragment bands; the C-terminal fragment additionally forms high-MW multimer products through 
thiol ester-mediated conjugation. When the bait region is impermissible to trypsin or LysC cleavage, A2M is 
cleaved outside of the bait region without any activation if its thiol ester. A2M TR K704 forms an intense 
~250 kDa band upon proteolytic activation that was determined to arise from auto-conjugation, see Figure 3.  
 
FIGURE 3. Investigating auto-conjugation to a bait region lysine residue. (A) Wildtype A2M and A2M 
TR K704 were digested with trypsin with and without BAPN, a 70 Da nucleophile which competes for thiol 
ester conjugation, as well as with a Cy5-labelled trypsin (approximately 1:1 mol/mol dye:trypsin) and 
acetylated trypsin. The samples were analyzed by reducing SDS-PAGE. The investigated band (marked by 
an asterisk) was dependent on thiol ester-mediated conjugation, as it disappeared when BAPN was present. It 
did not contain Cy5-labelled trypsin. It became more intense if conjugation to trypsin itself was prevented by 
acetylation of trypsin’s lysine residues. (B) The suspected auto-conjugation band was digested in-gel with 
pepsin and the peptides were analyzed by LC-MS/MS. A cross-linked peptide containing the thiol ester 
peptide LQMPYGCGEQN and the bait region lysine peptide FTNSKIRKPKMCGGSGGSGGSGGSGGK 
cross-linked together by an isopeptide bond was identified from this MS2 spectrum. b- and y-type product 
ions are colored according to the fragmented peptide; some product ions resulted from fragmentation in both 
peptides. Note that the y axis is truncated to 24% in the first panel due to the high intensity of the b2 ion with 
the sequence LQ.  
 
FIGURE 4. Inhibition of trypsin by tabula rasa-based A2Ms. (A) Bait region sequences for all A2M 
proteins for which the inhibition of trypsin was determined. (B) The inhibition of trypsin’s cleavage activity 
towards DQ-labelled gelatin by the indicated A2M mutants was determined. Fitting of the experimental data 
points for each mutant was performed by linear regression. Error bars show the standard deviation and each 
sample was prepared in triplicate. (C) The inhibition of trypsin by plasma-purified A2M, A2M TR K710, 









competes the covalent conjugation of other nucleophiles. Except for the use of BAPN where noted, the 
experiment and analysis were performed as in panel (B). 
 
FIGURE 5. Incorporation of MMP2 substrate sites into tabula rasa A2M. (A) Bait region sequences for 
wildtype A2M, tabula rasa A2M, and four TR bait regions each incorporating a different MMP2 substrate 
sequence (A21A, B74, C9, and S1). The MMP2 recognition sequence is colored orange; cleavage occurs at 
the N-terminus of the hydrophobic residue that is bolded. (B) A2Ms with these 6 bait regions were digested 
by MMP2 and nine other human proteases (see Supplementary Figure S6). Proteases which are able to 
cleave a bait region are indicated with a + in the case of full cleavage and (+) in the case of partial cleavage. 
The tabula rasa bait region was not cleaved by any tested protease, whereas each MMP2 substrate was 
cleaved by every tested MMP. The TR S1 bait region was not cleaved by proteases other than MMPs, 
indicating an increased selectivity of inhibition relative to the wildtype bait region. (C-D) Pore-limited native 
PAGE and reducing SDS-PAGE, respectively, of the six A2Ms with and without MMP2 cleavage. All 
constructs are similarly bait region-cleaved by MMP2, resulting in a conformational collapse and the 
appearance of high-MW multimer products in SDS-PAGE, with the exception of A2M TR. 
 
FIGURE 6. Optimization of the production and inhibitory capacity of A2M TR S1. (A) Several 
modifications of the MMP2 substrate bait region, tabula rasa S1, were tested for their ability to improve the 
formation of native A2M and its inhibitory capacity towards MMP2. TR S1 QRT4 re-introduces the fourth 
quarter of the wildtype bait region. Two different S1 positions (with cleavage at position 710 or 703) were 
tested in TR∆7, which shortens the TR bait region by seven residues. (B) Pore-limited native PAGE of 
A2Ms with the indicated bait regions. A2M TR S1 is expressed with a substantial amount of non-native 
A2M. This non-native A2M could be removed by depletion using LRP1-conjugated resin. Alternatively, the 
native content was improved in TR∆7 and TR QRT4. (C) The ability of the indicated A2Ms to inhibit 
MMP2’s digestion of DQ-gelatin was determined. Fitted curves calculated from the experimental data points 
by linear regression are shown as dotted lines. Error bars show the standard deviation and each sample was 
prepared in triplicate. 
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